scholarly journals The Effect of Caffeine on the Risk and Progression of Parkinson’s Disease: A Meta-Analysis

Nutrients ◽  
2020 ◽  
Vol 12 (6) ◽  
pp. 1860 ◽  
Author(s):  
Chien Tai Hong ◽  
Lung Chan ◽  
Chyi-Huey Bai
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Disease Risk ◽  
Meta Analysis ◽  
Motor Fluctuation ◽  
New Drugs ◽  
Caffeine Consumption ◽  
Healthy Cohort ◽  
Adenosine 2A Receptor

Coffee and caffeine are speculated to be associated with the reduced risk of Parkinson’s disease (PD). The present study aimed to investigate the disease-modifying potential of caffeine on PD, either for healthy people or patients, through a meta-analysis. The electronic databases were searched using terms related to PD and coffee and caffeinated food products. Articles were included only upon fulfillment of clear diagnostic criteria for PD and details regarding their caffeine content. Reference lists of relevant articles were reviewed to identify eligible studies not shortlisted using these terms. In total, the present study enrolled 13 studies, nine were categorized into a healthy cohort and the rest into a PD cohort. The individuals in the healthy cohort with regular caffeine consumption had a significantly lower risk of PD during follow-up evaluation (hazard ratio (HR) = 0.797, 95% CI = 0.748–0.849, p < 0.001). The outcomes of disease progression in PD cohorts included dyskinesia, motor fluctuation, symptom onset, and levodopa initiation. Individuals consuming caffeine presented a significantly lower rate of PD progression (HR = 0.834, 95% CI = 0.707–0.984, p = 0.03). In conclusion, caffeine modified disease risk and progression in PD, among both healthy individuals or those with PD. Potential biological benefits, such as those obtained from adenosine 2A receptor antagonism, may require further investigation for designing new drugs.

Course of cognitive decline in Parkinson's disease: A meta-analysis

2007 ◽  
Vol 13 (6) ◽  
pp. 920-932 ◽  
Author(s):  
DINO MUSLIMOVIĆ ◽  
BEN SCHMAND ◽  
JOHANNES D. SPEELMAN ◽  
ROB J. DE HAAN
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Cognitive Ability ◽  
Educational Level ◽  
Meta Analysis ◽  
Effect Sizes ◽  
Neuropsychological Performance ◽  
Significant Relation ◽  
Cognitive Domains

A meta-analysis was conducted on 25 longitudinal studies involving 901 initially non-demented Parkinson's disease (PD) patients to examine the magnitude of decline across multiple cognitive domains associated with disease progression. Pooled effect sizes reflecting the standardized difference between baseline and follow-up neuropsychological performance were calculated for 8 cognitive domains using a random-effects model. Relatively small effect sizes were found across all cognitive domains (d= .00 − .40). During a mean follow-up interval of 29 months, significant declines were detected in global cognitive ability (d= .40), visuoconstructive skills (d= .32), and memory (d= .29). Age showed a significant relation with decline in global cognitive ability and memory. Lower educational level was associated with greater decline in all cognitive domains. Studies with longer follow-up intervals yielded larger effect sizes for global cognitive ability. In non-demented PD patients, changes in cognitive functions over time appear to be modest. Educational level, age, and length of the follow-up interval are likely to affect the magnitude of decline in several domains. Methodological flaws, such as selection bias and uncontrolled practice effects, may have caused underestimation of the true extent of decline (JINS, 2007,13, 920–932.)

scholarly journals A Meta-Analysis on the Efficacy of Tai Chi in Patients with Parkinson’s Disease between 2008 and 2014

2015 ◽  
Vol 2015 ◽  
pp. 1-9 ◽  
Author(s):  
Ji Zhou ◽  
Tao Yin ◽  
Qian Gao ◽  
Xiao Cun Yang
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Motor Function ◽  
Tai Chi ◽  
Meta Analysis ◽  
Sufficient Evidence ◽  
Gait Velocity ◽  
Valid Evidence

Objective. The purpose of this systematic review is to evaluate the evidence on the effect of Tai Chi for Parkinson’s disease (PD).Methods. Six electronic databases up to June 2014 were searched. The methodological quality was assessed with PEDro scale. Standardised mean difference and 95% confidence intervals of random-effects model were calculated.Results. Nine studies were included in our review. The aggregated results are in favor of Tai Chi on improving motor function (P=0.002) and balance (P<0.00001) in patients with PD. However, there is no sufficient evidence to support or refute the value of Tai Chi on improving gait velocity (P=0.11), stride length (P=0.21), or quality of life (P=0.40). And there is no valid evidence in follow-up effects of Tai Chi for PD. Conclusion. The current results suggest that Tai Chi can significantly improve the motor function and balance in patients with PD, but there is indeed not enough evidence to conclude that Tai Chi is effective for PD because of the small treatment effect, methodological flaws of eligible studies, and insufficient follow-up. Consequently, high-quality studies with long follow-up are warranted to confirm current beneficial findings.

scholarly journals Common X-chromosome variants are associated with Parkinson’s disease risk

2020 ◽  
Author(s):  
Yann Le Guen ◽  
Valerio Napolioni ◽  
Michael E. Belloy ◽  
Eric Yu ◽  
Lynne Krohn ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
X Chromosome ◽  
Ribosomal Proteins ◽  
Disease Risk ◽  
Meta Analysis ◽  
European Ancestry ◽  
Density Region ◽  
Parental History ◽  
Genome Wide

AbstractObjectiveIdentify genetic variants on the X-chromosome associated with Parkinson’s disease (PD) risk.MethodsWe performed an X-chromosome-wide association study (XWAS) of PD risk by meta-analyzing results from sex-stratified analyses. To avoid spurious associations, we designed a specific harmonization pipeline for the X-chromosome and focused on a European ancestry sample. We included 11,324 cases, 280,060 controls, and 5,379 proxy cases, based on parental history of PD. Additionally, we tested the association of significant variants with: (i) PD risk in an independent replication with 1,564 cases and 2,467 controls, and (ii) putamen volume in 33,360 individuals from the UK Biobank.ResultsIn the discovery meta-analysis, we identified: rs7066890 (OR=1.10 [1.06-1.14]; P=2.2×10−9) intron of GPM6B, and rs28602900 (OR=1.10 [1.07-1.14]; P=1.6×10−8) in a high gene density region including RPL10, ATP6A1, FAM50A, PLXNA3. The rs28602900 association with PD was replicated (OR=1.16 [1.03-1.30]; P=0.016) and shown to colocalize with a significant expression quantitative locus (eQTL) regulating RPL10 expression in the putamen and other brain tissues in GTEx. Additionally, the rs28602900 locus was found to be associated with reduced brain putamen volume. No results reached genome-wide significance in the sex-stratified analyses.InterpretationWe report the first XWAS of PD and identify two genome-wide significant loci. The rs28602900 association replicated in an independent PD dataset and showed concordant effects in its association with putamen volume. Critically, rs26802900 is a significant eQTL of RPL10.These results support a role for ribosomal proteins in PD pathogenesis and show that the X-chromosome contributes to PD genetic risk.

scholarly journals Parkinson’s disease in Gaucher disease patients: what’s changing in the counseling and management of patients and their relatives?

2020 ◽  
Vol 15 (1) ◽  
Author(s):  
Maja Di Rocco ◽  
Alessio Di Fonzo ◽  
Antonio Barbato ◽  
Maria Domenica Cappellini ◽  
Francesca Carubbi ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Gaucher Disease ◽  
Disease Risk ◽  
Healthcare Providers ◽  
Family Members ◽  
Lifetime Risk ◽  
Specific Therapy ◽  
Inaccurate Information

Abstract Background How to address the counseling of lifetime risk of developing Parkinson’s disease in patients with Gaucher disease and their family members carrying a single variant of the GBA1 gene is not yet clearly defined. In addition, there is no set way of managing Gaucher disease patients, taking into account the possibility that they may show features of Parkinson’s disease. Methods Starting from an overview on what has recently changed in our knowledge on this issue and grouping the experiences of healthcare providers of Gaucher disease patients, we outline a path of counseling and management of Parkinson’s disease risk in Gaucher disease patients and their relatives. Conclusion The approach proposed here will help healthcare providers to communicate Parkinson’s disease risk to their patients and will reduce the possibility of patients receiving inaccurate information from inadequate sources. Furthermore, this resource will help to empower healthcare providers to identify early signs and/or symptoms of Parkinson’s disease and decide when to refer these patients to the neurologist for appropriate specific therapy and follow-up.

Glutathione S-transferase T1 and M1 null genotypes and Parkinson’s disease risk: evidence from an updated meta-analysis

2015 ◽  
Vol 36 (9) ◽  
pp. 1559-1565 ◽  
Author(s):  
Hongzhou Liu ◽  
Jie Peng ◽  
Jiajia Gao ◽  
Fang Zheng ◽  
Chaorong Tie
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Disease Risk ◽  
Meta Analysis ◽  
Glutathione S Transferase

Association between VPS13C rs2414739 polymorphism and Parkinson’s disease risk: A meta-analysis

2021 ◽  
pp. 135879
Author(s):  
Xinling Bai ◽  
Xian Liu ◽  
Xiaoyuan Li ◽  
Wenjian Li ◽  
Anmu Xie
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Disease Risk ◽  
Meta Analysis

Ventilatory Impairments Associated with Parkinson’s Disease: A Systematic Review and Meta-Analysis

Respiration ◽  
2021 ◽  
pp. 1-9
Author(s):  
Laura López-López ◽  
Janet Remedios Rodríguez-Torres ◽  
Lawrence Patrick Cahalin ◽  
Irene Cabrera-Martos ◽  
Irene Torres Sánchez ◽  
...  
Keyword(s):  
Systematic Review ◽  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Vital Capacity ◽  
Meta Analysis ◽  
Forced Expiratory Volume ◽  
Cochrane Library ◽  
Respiratory Impairment ◽  
Future Studies

<b><i>Background:</i></b> The peripheral and central repercussions of Parkinson’s disease (PD) affect the neuromuscular system producing a loss of muscle strength that can influence the respiratory system. Although several studies have examined various respiratory aspects of PD, to the best of our knowledge no study to date has systematically reviewed the existing data. <b><i>Objectives:</i></b> To examine the available literature related to the respiratory impairment in PD patients. <b><i>Methods:</i></b> We used PRISMA guidelines when reporting this review. We searched Pubmed, Cinhal, SciELO, and Cochrane Library, from inception until August 2018. Main variables assessed were forced vital capacity percent predicted (FVC%) and forced expiratory volume in 1 s percent predicted (FEV<sub>1</sub>%) for PD patients. <b><i>Results:</i></b> Six studies were included in this systematic review and meta-analysis. The obtained results concluded that PD patients present poorer pulmonary function when compared to healthy controls. When PD patients were compared between ON and OFF states, the results reviewed are in favour of the ON state. In the meta-analysis performed for FVC% and FEV<sub>1</sub>%, the results fail to find significant differences between PD patients and controls (<i>p</i> = 0.336 and <i>p</i> = 0.281, respectively), and between PD ON and OFF states (<i>p</i> = 0.109 and <i>p</i> = 0.059, respectively). <b><i>Conclusions:</i></b> We conclude that PD patients have impaired respiratory capacities that are related to the PD severity, time since diagnosis, and OFF state. Adequate follow-up of the respiratory function and studies focused on PD phenotypes have to be considered in future studies.

Sign in / Sign up

Export Citation Format

Share Document